Dosing & Uses
Dosage Forms & Strengths
tablet
- 200mg
- 300mg
- 400mg
Bronchitis Exacerbation
400 mg PO q12hr for 10 days
Limitations-of-use: Reserve antimicrobials#fluoroquinolones for patients who do not have other available treatment options for acute bacterial exacerbation of chronic bronchitis
Community Acquired Pneumonia
400 mg PO q12hr for 10 days
Skin & Skin Structure Infections
400 mg PO q12hr for 10 days
Acute, Uncomplicated Urethral and Cervical Gonorrhea
No longer recommended for gonorrhea owing to widespread resistance in the US
400 mg PO single dose
Nongonococcal Cervicitis/Urethritis or Mixed Infection of Cervix/Urethra
300 mg PO q12hr for 7 days
Acute Pelvic Inflammatory Disease
400 mg PO q12hr for 10-14 days
Uncomplicated Cystitis
Due to E. coli or K. pneumoniae: 200 mg PO q12hr for 3 days
Due to other approved pathogens: 200 mg PO q12hr for 7 days
Limitations-of-use: Reserve antimicrobials#fluoroquinolones for patients who do not have other available treatment options for uncomplicated urinary tract infections
Complicated UTIs
200 mg PO q12hr for 10 days
Prostatitis Due to E. Coli
300 mg PO q12hr for 6 weeks
Traveler's Diarrhea (Off-label)
300 mg PO q12hr for 1-3 days
Dosage Modifications
Renal impairment
- CrCl 20-50 mL/min: Give q24hr
- CrCl <20 mL/min: Give one-half usual dose q24hr
Other Indications and Uses
Mild to moderate infection due to susceptible strains of designated microorganisms
Chlamydia trachomatis, Citrobacter spp, Enterobacter spp, E. coli, Klebsiella pneumoniae, N. gonorrhoeae, Proteus mirabilis, Pseudomonas aeruginosa, S. aureus, S. pneumoniae
Culture and susceptibility tests needed to isolate and identify organisms
Safety and efficacy not established
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (1)
- fezolinetant
ofloxacin will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitors
Serious - Use Alternative (74)
- adagrasib
adagrasib, ofloxacin. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.
- aluminum hydroxide
aluminum hydroxide decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.
- aminolevulinic acid oral
aminolevulinic acid oral, ofloxacin. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period.
- aminolevulinic acid topical
ofloxacin increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.
- amiodarone
amiodarone and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- amisulpride
amisulpride and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- anagrelide
anagrelide and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- apomorphine
apomorphine and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- arsenic trioxide
arsenic trioxide and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- artemether
artemether and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- asenapine
asenapine and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- asenapine transdermal
asenapine transdermal and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- BCG vaccine live
ofloxacin decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.
- buprenorphine
buprenorphine and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine buccal
buprenorphine buccal and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine subdermal implant
buprenorphine subdermal implant and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine transdermal
buprenorphine transdermal and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- carbonyl iron
carbonyl iron decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- ceritinib
ceritinib and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- cholera vaccine
ofloxacin, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.
- desflurane
desflurane and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- didanosine
didanosine decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Applies to didanosine chewable tablets and powder for oral solution; administer 2 hr before or several hours after didanosine oral solution or chewable tablet administration; separate by 4-8 hours.
- disopyramide
disopyramide and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- encorafenib
encorafenib and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- entrectinib
ofloxacin and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.
- eribulin
eribulin and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- ferric maltol
ferric maltol decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- ferrous fumarate
ferrous fumarate decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- ferrous gluconate
ferrous gluconate decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- ferrous sulfate
ferrous sulfate decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- fexinidazole
fexinidazole and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.
- glasdegib
ofloxacin and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.
- hydroxychloroquine sulfate
hydroxychloroquine sulfate and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- ibutilide
ibutilide and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- indapamide
indapamide and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- inotuzumab
inotuzumab and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.
- iron dextran complex
iron dextran complex decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- iron sucrose
iron sucrose decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- isoflurane
isoflurane and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- ivosidenib
ivosidenib and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.
- lefamulin
lefamulin and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- macimorelin
macimorelin and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.
- methyl aminolevulinate
ofloxacin, methyl aminolevulinate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.
- microbiota oral
ofloxacin decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. .
- mobocertinib
mobocertinib and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.
- ondansetron
ofloxacin and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
- oxaliplatin
oxaliplatin and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- panobinostat
ofloxacin and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.
- pentamidine
ofloxacin and pentamidine both increase QTc interval. Avoid or Use Alternate Drug.
- pimozide
ofloxacin and pimozide both increase QTc interval. Avoid or Use Alternate Drug.
- pirfenidone
ofloxacin will increase the level or effect of pirfenidone by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating pirfenidone and avoided during treatment; if strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended
- pitolisant
ofloxacin and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.
- polysaccharide iron
polysaccharide iron decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- pomalidomide
ofloxacin increases levels of pomalidomide by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug.
- procainamide
ofloxacin and procainamide both increase QTc interval. Avoid or Use Alternate Drug.
- quinidine
quinidine and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- ribociclib
ribociclib increases toxicity of ofloxacin by QTc interval. Avoid or Use Alternate Drug.
- rose hips
rose hips decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- selinexor
selinexor, ofloxacin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
- siponimod
siponimod and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- sodium bicarbonate
sodium bicarbonate decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.
- sodium citrate/citric acid
sodium citrate/citric acid decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.
- sotalol
ofloxacin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
- strontium ranelate
strontium ranelate decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Suspend strontium ranelate during antibiotic therapy.
- tetrabenazine
tetrabenazine and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- toremifene
ofloxacin and toremifene both increase QTc interval. Avoid or Use Alternate Drug. Concurrent use of toremifene with agents causing QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
- tretinoin
ofloxacin, tretinoin. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.
- tretinoin topical
ofloxacin, tretinoin topical. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.
- typhoid vaccine live
ofloxacin decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.
- umeclidinium bromide/vilanterol inhaled
ofloxacin increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
- vandetanib
ofloxacin, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.
- vemurafenib
vemurafenib and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.
- vilanterol/fluticasone furoate inhaled
ofloxacin increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
Monitor Closely (195)
- acarbose
ofloxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- albuterol
albuterol and ofloxacin both increase QTc interval. Use Caution/Monitor.
- alfuzosin
ofloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and ofloxacin both increase QTc interval. Use Caution/Monitor. - amifampridine
ofloxacin increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.
- amiodarone
amiodarone will increase the level or effect of ofloxacin by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
- amitriptyline
amitriptyline and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- amoxapine
amoxapine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- arformoterol
arformoterol and ofloxacin both increase QTc interval. Use Caution/Monitor.
- aripiprazole
aripiprazole and ofloxacin both increase QTc interval. Use Caution/Monitor.
- artemether/lumefantrine
artemether/lumefantrine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- atomoxetine
atomoxetine and ofloxacin both increase QTc interval. Use Caution/Monitor.
- bazedoxifene/conjugated estrogens
ofloxacin will decrease the level or effect of bazedoxifene/conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- bedaquiline
ofloxacin and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely
- betamethasone
betamethasone and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.
- calcium acetate
calcium acetate, ofloxacin. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- calcium carbonate
calcium carbonate, ofloxacin. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- calcium chloride
calcium chloride, ofloxacin. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- calcium citrate
calcium citrate, ofloxacin. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- calcium gluconate
calcium gluconate, ofloxacin. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- chlorpromazine
chlorpromazine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- chlorpropamide
ofloxacin increases effects of chlorpropamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- citalopram
ofloxacin and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
- clarithromycin
clarithromycin and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- clomipramine
clomipramine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- clozapine
clozapine and ofloxacin both increase QTc interval. Use Caution/Monitor.
- conjugated estrogens
ofloxacin will decrease the level or effect of conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- corticotropin
corticotropin and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.
- cortisone
cortisone and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.
- crizotinib
crizotinib and ofloxacin both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
- dasatinib
dasatinib and ofloxacin both increase QTc interval. Use Caution/Monitor.
- degarelix
degarelix and ofloxacin both increase QTc interval. Use Caution/Monitor.
- desipramine
desipramine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- deutetrabenazine
deutetrabenazine and ofloxacin both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).
- dexamethasone
dexamethasone and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.
- dienogest/estradiol valerate
ofloxacin will decrease the level or effect of dienogest/estradiol valerate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. An alternate or additional form of birth control may be advisable during concomitant use.
- digoxin
ofloxacin will increase the level or effect of digoxin by altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.
digoxin will increase the level or effect of ofloxacin by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor. - dofetilide
dofetilide will increase the level or effect of ofloxacin by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
dofetilide and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely. - dolasetron
dolasetron and ofloxacin both increase QTc interval. Use Caution/Monitor.
- donepezil
donepezil and ofloxacin both increase QTc interval. Use Caution/Monitor.
- doxepin
doxepin and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- dronedarone
dronedarone and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- droperidol
droperidol and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- efavirenz
efavirenz and ofloxacin both increase QTc interval. Use Caution/Monitor.
- eliglustat
eliglustat and ofloxacin both increase QTc interval. Use Caution/Monitor.
- eluxadoline
ofloxacin increases levels of eluxadoline by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP1A2 inhibitors.
- epinephrine
epinephrine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- epinephrine racemic
epinephrine racemic and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- erythromycin base
erythromycin base and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- erythromycin ethylsuccinate
erythromycin ethylsuccinate and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- erythromycin lactobionate
erythromycin lactobionate and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- erythromycin stearate
erythromycin stearate and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- escitalopram
escitalopram increases toxicity of ofloxacin by QTc interval. Use Caution/Monitor.
- estradiol
ofloxacin will decrease the level or effect of estradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- estrogens conjugated synthetic
ofloxacin will decrease the level or effect of estrogens conjugated synthetic by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- estropipate
ofloxacin will decrease the level or effect of estropipate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- ethinylestradiol
ofloxacin will decrease the level or effect of ethinylestradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- ethotoin
ofloxacin decreases effects of ethotoin by unknown mechanism. Use Caution/Monitor. There are also case reports of quinolones increasing phenytoin levels.
- ezogabine
ezogabine, ofloxacin. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.
- fennel
fennel decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
- ferric citrate
ferric citrate will decrease the level or effect of ofloxacin by drug binding in GI tract. Use Caution/Monitor. Administer at least 2 hours before or after ferric citrate
- fingolimod
fingolimod and ofloxacin both increase QTc interval. Use Caution/Monitor.
- flecainide
flecainide and ofloxacin both increase QTc interval. Use Caution/Monitor.
- fluconazole
fluconazole and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- fludrocortisone
fludrocortisone and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.
- fluoxetine
fluoxetine and ofloxacin both increase QTc interval. Use Caution/Monitor.
- fluphenazine
fluphenazine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- fluvoxamine
fluvoxamine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- formoterol
formoterol and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- foscarnet
foscarnet and ofloxacin both increase QTc interval. Use Caution/Monitor.
- fosphenytoin
ofloxacin decreases effects of fosphenytoin by unknown mechanism. Use Caution/Monitor. There are also case reports of quinolones increasing phenytoin levels.
- fostemsavir
ofloxacin and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
- gemtuzumab
ofloxacin and gemtuzumab both increase QTc interval. Use Caution/Monitor.
- gilteritinib
gilteritinib and ofloxacin both increase QTc interval. Use Caution/Monitor.
- glimepiride
ofloxacin increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- glipizide
ofloxacin increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- glyburide
ofloxacin increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- goserelin
goserelin increases toxicity of ofloxacin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- granisetron
granisetron and ofloxacin both increase QTc interval. Use Caution/Monitor.
- haloperidol
haloperidol and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- histrelin
histrelin increases toxicity of ofloxacin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- hydrocortisone
hydrocortisone and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.
- hydrocortisone rectal
hydrocortisone rectal and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.
- hydroxyzine
hydroxyzine and ofloxacin both increase QTc interval. Use Caution/Monitor.
- ibuprofen IV
ofloxacin, ibuprofen IV. Other (see comment). Use Caution/Monitor. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- iloperidone
iloperidone and ofloxacin both increase QTc interval. Use Caution/Monitor.
- imipramine
imipramine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- indacaterol, inhaled
indacaterol, inhaled, ofloxacin. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.
- insulin aspart
ofloxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- insulin detemir
ofloxacin increases effects of insulin detemir by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- insulin glargine
ofloxacin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- insulin glulisine
ofloxacin increases effects of insulin glulisine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- insulin lispro
ofloxacin increases effects of insulin lispro by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- insulin NPH
ofloxacin increases effects of insulin NPH by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- insulin regular human
ofloxacin increases effects of insulin regular human by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- itraconazole
itraconazole and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- ketoconazole
ketoconazole and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- lanthanum carbonate
lanthanum carbonate decreases levels of ofloxacin by cation binding in GI tract. Use Caution/Monitor. Administer oral quinolone antibiotics at least 1 hr before or 4 hr after lanthanum. Interaction applies only to oral quinolones.
- lapatinib
lapatinib and ofloxacin both increase QTc interval. Use Caution/Monitor.
- lenvatinib
ofloxacin and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.
- leuprolide
leuprolide increases toxicity of ofloxacin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- levofloxacin
levofloxacin and ofloxacin both increase QTc interval. Use Caution/Monitor.
- levoketoconazole
levoketoconazole and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- levonorgestrel oral/ethinylestradiol/ferrous bisglycinate
ofloxacin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy.
- lithium
lithium and ofloxacin both increase QTc interval. Use Caution/Monitor.
- lofepramine
lofepramine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- lumefantrine
lumefantrine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- magnesium chloride
magnesium chloride decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- magnesium citrate
magnesium citrate decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- magnesium hydroxide
magnesium hydroxide decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- magnesium oxide
magnesium oxide decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- magnesium sulfate
magnesium sulfate decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- maprotiline
maprotiline and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- mestranol
ofloxacin will decrease the level or effect of mestranol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- metformin
ofloxacin increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- methadone
methadone and ofloxacin both increase QTc interval. Use Caution/Monitor.
- methylprednisolone
methylprednisolone and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.
- mifepristone
mifepristone, ofloxacin. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.
- miglitol
ofloxacin increases effects of miglitol by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- mirtazapine
mirtazapine and ofloxacin both increase QTc interval. Use Caution/Monitor.
- mometasone inhaled
mometasone inhaled and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.
- moxifloxacin
moxifloxacin and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- nateglinide
ofloxacin increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- nilotinib
nilotinib and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- nortriptyline
nortriptyline and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- octreotide
octreotide and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- octreotide (Antidote)
octreotide (Antidote) and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- olanzapine
olanzapine and ofloxacin both increase QTc interval. Use Caution/Monitor.
- olodaterol inhaled
ofloxacin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias
- osilodrostat
osilodrostat and ofloxacin both increase QTc interval. Use Caution/Monitor.
- osimertinib
osimertinib and ofloxacin both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.
- oxaliplatin
oxaliplatin will increase the level or effect of ofloxacin by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.
- ozanimod
ozanimod and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.
- paliperidone
ofloxacin and paliperidone both increase QTc interval. Use Caution/Monitor.
- paroxetine
ofloxacin and paroxetine both increase QTc interval. Use Caution/Monitor.
- pasireotide
ofloxacin and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.
- pentoxifylline
ofloxacin will increase the level or effect of pentoxifylline by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.
- perphenazine
perphenazine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- phenytoin
ofloxacin decreases effects of phenytoin by unknown mechanism. Use Caution/Monitor. There are also case reports of quinolones increasing phenytoin levels.
- pioglitazone
ofloxacin increases effects of pioglitazone by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- posaconazole
ofloxacin and posaconazole both increase QTc interval. Use Caution/Monitor.
- prednisolone
prednisolone and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.
- prednisone
prednisone and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.
- primaquine
primaquine and ofloxacin both increase QTc interval. Use Caution/Monitor.
- procainamide
ofloxacin will increase the level or effect of procainamide by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
- prochlorperazine
prochlorperazine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- promazine
promazine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- promethazine
promethazine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- protriptyline
protriptyline and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- quetiapine
quetiapine, ofloxacin. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
- quinidine
quinidine will increase the level or effect of ofloxacin by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
- quinine
ofloxacin and quinine both increase QTc interval. Use Caution/Monitor.
- ranolazine
ofloxacin and ranolazine both increase QTc interval. Use Caution/Monitor.
- repaglinide
ofloxacin increases effects of repaglinide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- rilpivirine
rilpivirine increases toxicity of ofloxacin by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsade de Pointes.
- risperidone
ofloxacin and risperidone both increase QTc interval. Use Caution/Monitor.
- romidepsin
ofloxacin and romidepsin both increase QTc interval. Use Caution/Monitor.
- rosiglitazone
ofloxacin increases effects of rosiglitazone by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- saquinavir
saquinavir increases levels of ofloxacin by QTc interval. Modify Therapy/Monitor Closely. Potential for increased toxicity. Use alternatives if available. Increased risk of QT prolongation and cardiac arrhythmias.
- saxagliptin
ofloxacin increases effects of saxagliptin by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- selpercatinib
selpercatinib increases toxicity of ofloxacin by QTc interval. Use Caution/Monitor.
- sertraline
sertraline and ofloxacin both increase QTc interval. Use Caution/Monitor.
- sitagliptin
ofloxacin increases effects of sitagliptin by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- sodium picosulfate/magnesium oxide/anhydrous citric acid
ofloxacin decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.
sodium picosulfate/magnesium oxide/anhydrous citric acid decreases levels of ofloxacin by cation binding in GI tract. Use Caution/Monitor. Take at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid to avoid magnesium chelation. - sodium sulfate/?magnesium sulfate/potassium chloride
sodium sulfate/?magnesium sulfate/potassium chloride decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer fluoroquinolones at least 2 hr before and no less than 6 hr after each dose to avoid chelation with magnesium. .
- sodium sulfate/potassium sulfate/magnesium sulfate
sodium sulfate/potassium sulfate/magnesium sulfate decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer fluoroquinolones at least 2 hr before and no less than 6 hr after each dose to avoid chelation with magnesium. .
- solifenacin
solifenacin and ofloxacin both increase QTc interval. Use Caution/Monitor.
- sorafenib
sorafenib and ofloxacin both increase QTc interval. Use Caution/Monitor.
- sucralfate
sucralfate decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
- sulfamethoxazole
sulfamethoxazole and ofloxacin both increase QTc interval. Use Caution/Monitor.
- sunitinib
sunitinib and ofloxacin both increase QTc interval. Use Caution/Monitor.
- tacrolimus
tacrolimus and ofloxacin both increase QTc interval. Use Caution/Monitor.
- tasimelteon
ofloxacin will increase the level or effect of tasimelteon by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Avoid coadministration; potentially large increase in tasimelteon exposure and greater risk of adverse reactions with strong CYP1A2 inhibitors
- telavancin
ofloxacin and telavancin both increase QTc interval. Use Caution/Monitor.
- terbinafine
ofloxacin will increase the level or effect of terbinafine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.
- thioridazine
thioridazine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- tolazamide
ofloxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- tolbutamide
ofloxacin increases effects of tolbutamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- trazodone
trazodone and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- triamcinolone acetonide injectable suspension
triamcinolone acetonide injectable suspension and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.
- triclabendazole
triclabendazole and ofloxacin both increase QTc interval. Use Caution/Monitor.
- trifluoperazine
trifluoperazine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- trimagnesium citrate anhydrous
trimagnesium citrate anhydrous decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of quinolones; administer quinolone at least 2 hr before or 6 hr after magnesium; use alternatives if available.
- trimethoprim
ofloxacin and trimethoprim both increase QTc interval. Use Caution/Monitor.
- trimipramine
trimipramine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- triptorelin
triptorelin increases toxicity of ofloxacin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- tropisetron
ofloxacin and tropisetron both increase QTc interval. Use Caution/Monitor.
- valbenazine
valbenazine and ofloxacin both increase QTc interval. Use Caution/Monitor.
- venlafaxine
ofloxacin and venlafaxine both increase QTc interval. Use Caution/Monitor.
- vildagliptin
ofloxacin increases effects of vildagliptin by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
- voclosporin
voclosporin, ofloxacin. Either increases effects of the other by QTc interval. Use Caution/Monitor.
- voriconazole
ofloxacin and voriconazole both increase QTc interval. Use Caution/Monitor.
- vorinostat
vorinostat and ofloxacin both increase QTc interval. Use Caution/Monitor.
- warfarin
ofloxacin increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor.
- zinc
zinc will decrease the level or effect of ofloxacin by cation binding in GI tract. Modify Therapy/Monitor Closely. Administer oral ofloxacin 2 hr before or after administration of polyvalent cation containing products.
- ziprasidone
ofloxacin and ziprasidone both increase QTc interval. Modify Therapy/Monitor Closely.
Minor (92)
- acarbose
ofloxacin, acarbose. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- aceclofenac
ofloxacin, aceclofenac. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- acemetacin
ofloxacin, acemetacin. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- alprazolam
ofloxacin increases levels of alprazolam by decreasing metabolism. Minor/Significance Unknown.
- aspirin
ofloxacin, aspirin. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- aspirin rectal
ofloxacin, aspirin rectal. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- aspirin/citric acid/sodium bicarbonate
ofloxacin, aspirin/citric acid/sodium bicarbonate. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- azithromycin
azithromycin and ofloxacin both increase QTc interval. Minor/Significance Unknown.
- balsalazide
ofloxacin will decrease the level or effect of balsalazide by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- biotin
ofloxacin will decrease the level or effect of biotin by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- celecoxib
ofloxacin, celecoxib. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- chlordiazepoxide
ofloxacin increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.
- chloroquine
chloroquine increases toxicity of ofloxacin by QTc interval. Minor/Significance Unknown.
- chlorpropamide
ofloxacin, chlorpropamide. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- choline magnesium trisalicylate
ofloxacin, choline magnesium trisalicylate. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- clonazepam
ofloxacin increases levels of clonazepam by decreasing metabolism. Minor/Significance Unknown.
- clorazepate
ofloxacin increases levels of clorazepate by decreasing metabolism. Minor/Significance Unknown.
- diclofenac
ofloxacin, diclofenac. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- diflunisal
ofloxacin, diflunisal. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- estazolam
ofloxacin increases levels of estazolam by decreasing metabolism. Minor/Significance Unknown.
- etodolac
ofloxacin, etodolac. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- fenbufen
ofloxacin, fenbufen. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- fenoprofen
ofloxacin, fenoprofen. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- flurazepam
ofloxacin increases levels of flurazepam by decreasing metabolism. Minor/Significance Unknown.
- flurbiprofen
ofloxacin, flurbiprofen. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- foscarnet
ofloxacin, foscarnet. Mechanism: unknown. Minor/Significance Unknown. Risk of tonic clonic seizure.
- glimepiride
ofloxacin, glimepiride. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- glipizide
ofloxacin, glipizide. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- glyburide
ofloxacin, glyburide. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- hydrochlorothiazide
hydrochlorothiazide will increase the level or effect of ofloxacin by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- ibuprofen
ofloxacin, ibuprofen. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- indomethacin
ofloxacin, indomethacin. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- insulin aspart
ofloxacin, insulin aspart. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- insulin detemir
ofloxacin, insulin detemir. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- insulin glargine
ofloxacin, insulin glargine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- insulin glulisine
ofloxacin, insulin glulisine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- insulin lispro
ofloxacin, insulin lispro. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- insulin NPH
ofloxacin, insulin NPH. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- insulin regular human
ofloxacin, insulin regular human. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- isotretinoin
ofloxacin, isotretinoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity.
- ketoprofen
ofloxacin, ketoprofen. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- ketorolac
ofloxacin, ketorolac. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- ketorolac intranasal
ofloxacin, ketorolac intranasal. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- loprazolam
ofloxacin increases levels of loprazolam by decreasing metabolism. Minor/Significance Unknown.
- lorazepam
ofloxacin increases levels of lorazepam by decreasing metabolism. Minor/Significance Unknown.
- lormetazepam
ofloxacin increases levels of lormetazepam by decreasing metabolism. Minor/Significance Unknown.
- lornoxicam
ofloxacin, lornoxicam. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- meclofenamate
ofloxacin, meclofenamate. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- mefenamic acid
ofloxacin, mefenamic acid. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- meloxicam
ofloxacin, meloxicam. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- memantine
memantine will increase the level or effect of ofloxacin by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- metformin
metformin will increase the level or effect of ofloxacin by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
ofloxacin, metformin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia. - methyclothiazide
methyclothiazide will increase the level or effect of ofloxacin by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- midazolam
ofloxacin increases levels of midazolam by decreasing metabolism. Minor/Significance Unknown.
- midodrine
midodrine will increase the level or effect of ofloxacin by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- miglitol
ofloxacin, miglitol. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- nabumetone
ofloxacin, nabumetone. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- naproxen
ofloxacin, naproxen. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- nateglinide
ofloxacin, nateglinide. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- oxaprozin
ofloxacin, oxaprozin. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- oxazepam
ofloxacin increases levels of oxazepam by decreasing metabolism. Minor/Significance Unknown.
- pantothenic acid
ofloxacin will decrease the level or effect of pantothenic acid by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- parecoxib
ofloxacin, parecoxib. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- pazopanib
ofloxacin and pazopanib both increase QTc interval. Minor/Significance Unknown.
- pioglitazone
ofloxacin, pioglitazone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- piroxicam
ofloxacin, piroxicam. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- pyridoxine
ofloxacin will decrease the level or effect of pyridoxine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- pyridoxine (Antidote)
ofloxacin will decrease the level or effect of pyridoxine (Antidote) by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- quazepam
ofloxacin increases levels of quazepam by decreasing metabolism. Minor/Significance Unknown.
- quercetin
quercetin decreases effects of ofloxacin by pharmacodynamic antagonism. Minor/Significance Unknown.
- quinine
ofloxacin will increase the level or effect of quinine by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- repaglinide
ofloxacin, repaglinide. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- rosiglitazone
ofloxacin, rosiglitazone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- salicylates (non-asa)
ofloxacin, salicylates (non-asa). Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- salsalate
ofloxacin, salsalate. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- saxagliptin
ofloxacin, saxagliptin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- sevoflurane
sevoflurane and ofloxacin both increase QTc interval. Minor/Significance Unknown.
- sitagliptin
ofloxacin, sitagliptin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- sulfamethoxazole
sulfamethoxazole will increase the level or effect of ofloxacin by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- sulfasalazine
ofloxacin, sulfasalazine. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- sulindac
ofloxacin, sulindac. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- temazepam
ofloxacin increases levels of temazepam by decreasing metabolism. Minor/Significance Unknown.
- thiamine
ofloxacin will decrease the level or effect of thiamine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- tolazamide
ofloxacin, tolazamide. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- tolbutamide
ofloxacin, tolbutamide. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
- tolfenamic acid
ofloxacin, tolfenamic acid. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- tolmetin
ofloxacin, tolmetin. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.
- triamterene
ofloxacin will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- triazolam
ofloxacin increases levels of triazolam by decreasing metabolism. Minor/Significance Unknown.
- trimethoprim
ofloxacin will increase the level or effect of trimethoprim by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- verapamil
ofloxacin will increase the level or effect of verapamil by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- vildagliptin
ofloxacin, vildagliptin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
Adverse Effects
1-10%
Nausea (3-10%)
Headache (1-9%)
Insomnia (3-7%)
Dizziness (1-5%)
Vaginitis (1-5%)
Diarrhea (1-4%)
Vomiting (1-4%)
Appetite decreased (1-3%)
Abdominal cramps (1-3%)
Abnormal taste (1-3%)
Chest pain (1-3%)
External genital pruritis in women (1-3%)
Fatigue (1-3%)
Flatulence (1-3%)
GI distress (1-3%)
Nervousness (1-3%)
Pharyngitis (1-3%)
Pyrexia (1-3%)
Rash/pruritis (1-3%)
Sleep disorders (1-3%)
Visual disturbances (1-3%)
Xerostomia (1-3%)
<1%
Prolonged QT interval
Torsades de pointes
Syncope
Vasculitis
Edema
HTN
Palpitations
Vasodilation
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Agranulocytosis
Aplastic anemia
Pancytopenia
Thrombocytopenia
Thrombocytopenic purpura
Acute hepatitis
Hepatic failure
Hepatic necrosis
Immune hypersensitivity reaction
Rupture of tendon, Tendinitis
Peripheral neuropathy
Seizure
Acute renal failure
Interstitial nephritis
Renal impairment
Tourette's syndrome
Decr hearing acuity
Tinnitus
Warnings
Black Box Warnings
Serious adverse effects
- Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together including: tendinitis and tendon rupture, peripheral neuropathy, and CNS effects
- Discontinue the drug immediately and avoid use of systemic antimicrobials#fluoroquinolones in patients who experience any of these serious adverse reactions
- May exacerbate muscle weakness in patients with myasthenia gravis; antimicrobials#fluoroquinolones should be avoided in patients with known history of myasthenia gravis
- Because antimicrobials#fluoroquinolones have been associated with serious adverse reactions, reserve drug use in patients who have no alternative treatment options for the following indications: Acute bacterial sinusitis; acute bacterial exacerbation of chronic bronchitis
Contraindications
Hypersensitivity to ofloxacin or any member of the quinolone class of antibacterials
Cautions
Fluoroquinolones been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient; adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion); discontinue treatment immediately at the first signs or symptoms of any serious adverse reaction; avoid use in patients who have experienced any of these serious adverse reactions
Fluoroquinolones have been associated with an increased risk of tendinitis and tendon rupture in all ages; adverse reaction most frequently involves the Achilles tendon, and has also been reported with the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendons (see Black Box Warnings)
In prolonged therapy, perform periodic evaluations of organ system function (eg, renal, hepatic, hematopoietic); superinfections may occur with prolonged or repeated antibiotic therapy
Antimicrobial agents used in high doses for short periods of time to treat gonorrhea may mask or delay symptoms of incubating syphilis; all patients with gonorrhea should have a serologic test for syphilis at time of diagnosis; patients treated for gonorrhea should have a follow-up serologic test for syphilis after three months and, if positive, treatment with an appropriate antimicrobial should be instituted
Administer ofloxacin with caution in presence of renal or hepatic insufficiency/impairment; in patients with known or suspected renal or hepatic insufficiency/impairment, perform careful clinical observation and appropriate laboratory studies prior to and during therapy; elimination of ofloxacin may be reduced; alteration of the dosage regimen is necessary in patients with impaired renal function (creatinine clearance <50 mg/mL)
Excessive exposure UV light or sun should be avoided; discontinue therapy if photosensitivity/phototoxicity occurs
Peripheral neuropathy: Sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias, and weakness reported; peripheral neuropathy may occur rapidly after initiating and may potentially become permanent
Serious, sometimes fatal hypoglycemia reported including in patients without a history of hypoglycemia (common with gatifloxacin, which is no longer marketed); monitor glucose levels closely in patients with diabetes; if hypoglycemic reaction occurs, discontinue therapy and initiate appropriate therapy immediately
Avoid use in presence of drugs or conditions that prolong QT interval, patients with known prolongation of the QT interval, patients with ventricular arrhythmias including torsade de pointes because QT prolongation may lead to an increased risk for these conditions, patients with ongoing proarrhythmic conditions, such as clinically significant bradycardia and acute myocardial ischemia or patients with hypokalemia or hypomagnesemia
Not drug of first choice in pediatrics due to increased incidence of adverse events compared to controls, including arthropathy; no data exist for dose for pediatric patients with renal impairment (ie, CrCl <50 mL/min)
Convulsions, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis reported with antimicrobials#fluoroquinolones
Adequate hydration of patients receiving therapy should be maintained to prevent formation of a highly concentrated urine
Prescribing therapy in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases risk of development of drug-resistant bacteria
Acute onset of retinal detachment increased 4.5-fold with oral antimicrobials#fluoroquinolones in a single case-controlled study - JAMA 2012;307(13):1414-1419; another study disputes these findings (relative risk, 1.29) - JAMA 2013;310(20):2184-2190
Clostridium difficile associated diarrhea (CDAD)
- CDAD reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of the colon leading to overgrowth of C. difficile
- C. difficile produces toxins A and B which contribute to development of CDAD; hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy; CDAD must be considered in all patients who present with diarrhea following antibiotic use; careful medical history is necessary since CDAD has been reported to occur over two months after administration of antibacterial agents
- If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued; institute appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation as clinically indicated
CNS effects
- Fluoroquinolones have been associated with an increased risk of CNS effects, including: convulsions, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis
- May also cause CNS events including: nervousness, agitation, insomnia, anxiety, nightmares, paranoia, dizziness, confusion, tremors, hallucinations, depression, and psychotic reactions have progressed to suicidal ideations/thoughts and self-injurious behavior such as attempted or completed suicide; reactions may occur following the first dose; advise patients to inform their healthcare provider immediately if these reactions occur, discontinue treatment, and institute appropriate care
- Fluoroquinolone are also known to trigger seizures or lower the seizure threshold; use with caution in epileptic patients and patients with known or suspected CNS disorders that may predispose to seizures or lower the seizure threshold (eg, severe cerebral arteriosclerosis, previous history of convulsion, reduced cerebral blood flow, altered brain structure, or stroke), or in the presence of other risk factors that may predispose to seizures or lower the seizure threshold (eg, certain drug therapy, renal dysfunction)
FDA MedWatch Safety Alert
- Issued 12-20-2018
- FDA review found antimicrobials#fluoroquinolones can cause an increase in occurrence of aortic dissections
- May occur with antimicrobials#fluoroquinolones for systemic use (IV or PO)
- Patients who have an aortic aneurysm or are at risk for an aortic aneurysm (eg, patients with peripheral atherosclerotic vascular diseases, hypertension, certain genetic conditions [eg, Marfan syndrome, Ehlers-Danlos syndrome], elderly patients)
- Prescribe antimicrobials#fluoroquinolones to these patients only when no other treatment options are available
- Advise patients to seek immediate medical treatment for any symptoms associated with aortic aneurysm
- Stop fluoroquinolone treatment immediately if a patient reports side effects suggestive of aortic aneurysm or dissecti
FDA MedWatch Safety Alert
- Issued July 10, 2018
- The FDA is strengthening the current warnings in the prescribing information for fluoroquinolone antibiotics to inform clinicians of significant decreases in blood glucose and certain mental health adverse effects
- Hypoglycemia, sometimes resulting in coma, occurred more frequently in elderly patients or in diabetic patients taking oral hypoglycemic medicine or insulin
- Alert patients regarding hypoglycemic symptoms and carefully monitor blood glucose levels; instruct patients how to treat themselves if symptoms of hypoglycemia occur
- This safety alert affects only systemic formulations; early signs and symptoms of low blood glucose include confusion, dizziness, feeling shaky, unusual hunger, headaches, irritability, pounding heart or very fast pulse, pale skin, sweating, trembling, weakness, and/or unusual anxiety
- Mental health side effects are to be added to or updated across all the antimicrobials#fluoroquinolones are disturbances in attention, disorientation, agitation, nervousness, memory impairment, and delirium
- Inform patients of the potential risk of psychiatric adverse reactions that can occur after just 1 dose
- Immediately discontinue treatment if CNS adverse effects occur, including psychiatric adverse reactions, or blood glucose disturbances occur and switch to a nonfluoroquinolone antibiotic if possible
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excreted in breast milk, discontinue drug or do not nurse
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Inhibits bacterial DNA gyrase, which in turn inhibits DNA replication and transcription, DNA repair, recombination and transposicion, causing bacterial cell death.
Absorption
Well absorbed; food causes only minor alterations
Bioavailability: 98%
Distribution
Protein Bound: 32%
Vd: 2.4-3.5 L/kg
Elimination
Half-Life: 4-5 hr
Excretion: Urine (up to 80% unchanged; <5% metabolites); feces 4-8%
Administration
Oral Administration
Do not take with antacids or dairy products
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| ofloxacin otic (ear) - | 0.3 % drops |  | |
| ofloxacin otic (ear) - | 0.3 % drops |  | |
| ofloxacin otic (ear) - | 0.3 % drops |  | |
| ofloxacin otic (ear) - | 0.3 % drops |  | |
| ofloxacin otic (ear) - | 0.3 % drops |  | |
| ofloxacin otic (ear) - | 0.3 % drops |  | |
| ofloxacin otic (ear) - | 0.3 % drops |  | |
| ofloxacin ophthalmic (eye) - | 0.3 % drops |  | |
| ofloxacin ophthalmic (eye) - | 0.3 % drops |  | |
| ofloxacin ophthalmic (eye) - | 0.3 % drops |  | |
| ofloxacin ophthalmic (eye) - | 0.3 % drops |  | |
| ofloxacin ophthalmic (eye) - | 0.3 % drops |  | |
| ofloxacin ophthalmic (eye) - | 0.3 % drops |  | |
| ofloxacin ophthalmic (eye) - | 0.3 % drops |  | |
| ofloxacin ophthalmic (eye) - | 0.3 % drops |  | |
| ofloxacin oral - | 400 mg tablet |  | |
| Ocuflox ophthalmic (eye) - | 0.3 % drops |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
ofloxacin ophthalmic (eye)
OFLOXACIN SOLUTION - OPHTHALMIC
(oh-FLOX-a-sin)
COMMON BRAND NAME(S): Ocuflox
USES: This medication is used to treat eye infections. Ofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria.This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.
HOW TO USE: To apply eye drops, wash your hands first. To avoid contamination, do not touch the dropper tip or let it touch your eye or any other surface.Do not wear contact lenses while you are using this medicine. Sterilize contact lenses according to manufacturer's directions and check with your doctor before using them.Tilt your head back, look upward and pull down the lower eyelid to make a pouch. Hold the dropper directly over the eye and place one drop into the eye. Look downward and gently close your eyes for 1 to 2 minutes. Place one finger at the corner of your eye (near the nose) and apply gentle pressure. This will prevent the medication from draining out. Try not to blink and do not rub your eye. Repeat these steps for your other eye if so directed, and if your dose is for more than 1 drop.Do not rinse the dropper. Replace the dropper cap after each use.If you are using another kind of eye medication (such as drops or ointments), wait at least 5 minutes before applying other medications. Use eye drops before eye ointments to allow the eye drops to enter the eye.Use this medication regularly in order to get the most benefit from it. Continue using it for the full time prescribed even if symptoms disappear after a few days. Stopping the medication too early may allow bacteria to continue to grow, which may result in a relapse of the infection.Inform your doctor if your condition lasts or gets worse.
SIDE EFFECTS: This medication may temporarily sting or burn your eyes for a minute or two when applied. Temporary blurred vision, eye discomfort, itching, redness, dryness, tearing, feeling as if something is in your eye, or sensitivity to light may occur. If any of these effects last or get worse, notify your doctor or pharmacist promptly.Remember that your doctor has prescribed this medication because the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Use of this medication for prolonged or repeated periods may result in a new fungal eye infection. Do not use it for longer than prescribed. Contact your doctor if you notice new or worsening symptoms.Tell your doctor right away if you have any serious side effects, including: eye pain, swelling of your eyelids or face.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before using ofloxacin, tell your doctor or pharmacist if you are allergic to it; or to other quinolones (such as ciprofloxacin, levofloxacin); or if you have any other allergies. This product may contain inactive ingredients (such as preservatives like benzalkonium chloride), which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: other eye problems.After you apply this drug, your vision may become temporarily blurred or unstable. Do not drive, use machinery, or do any activity that requires clear vision until you can do it safely.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this medication passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
OVERDOSE: This medicine may be harmful if swallowed. If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: Do not share this medication with others.This medication has been prescribed for your current condition only. Throw away the unused medication after treatment is completed. Do not use it later for another infection unless your doctor tells you to.
MISSED DOSE: If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Use your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature. Discard the solution if it changes color, becomes cloudy, or develops particles. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised May 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
